Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

BioSeed 2025

BioSeed, organised by OBN, is a fast-paced, one-day pitching event where early-stage life sciences companies seeking seed funding present to an audience of active investors. [...]

Go to Top